In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs ...
The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results